TY - JOUR
T1 - Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-Positive breast cancer patients treated with chemotherapy and HER2-Targeted agents in the CherLOB trial
AU - Dieci, M. V.
AU - Prat, Annik
AU - Tagliafico, Enrico
AU - Paré, Laia
AU - Ficarra, G.
AU - Bisagni, G.
AU - Piacentini, Federico
AU - Generali, D G
AU - Conte, P.
AU - Guarneri, V.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background: The aim of this work was to evaluate the impact of (and relative contribution of) tumor-related and immunerelated diversity of HER2-positive disease on the response to neoadjuvant chemotherapy plus anti-HER2 agents. Patients and methods: The CherLOB phase II study randomized 121 HER2-positive breast cancer patients to neoadjuvant chemotherapy plus trastuzumab, lapatinib or both. Tumor samples from diagnostic core biopsy were centralized. Tumor-infiltrating lymphocytes (TILs) were evaluated on H&slides. Intrinsic subtyping was carried out using the researchbased 50-gene prediction analysis of a microarray (PAM50) subtype predictor. Immune-related gene signatures were also evaluated. Results: Continuous Str-TILs and It-TILs were significantly associated with pCR [OR 1.03, 95% CI 1.02-1.05 (P < 0.001) and OR 1.09, 95% CI 1.04-1.15 (P < 0.001) for Str-TILs and It-TILs, respectively]. According to PAM50, the subtype distribution was as follows: HER2-enriched 26.7%, Luminal A 25.6%, Luminal B 16.3%, Basal-like 14% and Normal-like 17.4%. The highest rate of pCR was observed for the HER2-enriched subtype (50%), followed by Basal-like, Luminal B and Luminal A (x2 test, P = 0.026). Immune gene signatures significantly associated with pCR in univariate analyses were identified: most of them maintained a significant association with pCR in multivariate analyses corrected for PAM50 subtypes, whereas TILs did not. Conclusions: In this study, both tumor-related and immune-related features contribute to the modulation of pCR after neoadjuvant chemotherapy plus anti-HER2 agents. Immune signatures rather than TILs added significant prediction of pCR beyond PAM50 intrinsic subtypes.
AB - Background: The aim of this work was to evaluate the impact of (and relative contribution of) tumor-related and immunerelated diversity of HER2-positive disease on the response to neoadjuvant chemotherapy plus anti-HER2 agents. Patients and methods: The CherLOB phase II study randomized 121 HER2-positive breast cancer patients to neoadjuvant chemotherapy plus trastuzumab, lapatinib or both. Tumor samples from diagnostic core biopsy were centralized. Tumor-infiltrating lymphocytes (TILs) were evaluated on H&slides. Intrinsic subtyping was carried out using the researchbased 50-gene prediction analysis of a microarray (PAM50) subtype predictor. Immune-related gene signatures were also evaluated. Results: Continuous Str-TILs and It-TILs were significantly associated with pCR [OR 1.03, 95% CI 1.02-1.05 (P < 0.001) and OR 1.09, 95% CI 1.04-1.15 (P < 0.001) for Str-TILs and It-TILs, respectively]. According to PAM50, the subtype distribution was as follows: HER2-enriched 26.7%, Luminal A 25.6%, Luminal B 16.3%, Basal-like 14% and Normal-like 17.4%. The highest rate of pCR was observed for the HER2-enriched subtype (50%), followed by Basal-like, Luminal B and Luminal A (x2 test, P = 0.026). Immune gene signatures significantly associated with pCR in univariate analyses were identified: most of them maintained a significant association with pCR in multivariate analyses corrected for PAM50 subtypes, whereas TILs did not. Conclusions: In this study, both tumor-related and immune-related features contribute to the modulation of pCR after neoadjuvant chemotherapy plus anti-HER2 agents. Immune signatures rather than TILs added significant prediction of pCR beyond PAM50 intrinsic subtypes.
KW - Breast cancer
KW - HER2
KW - Immune signatures
KW - Neoadjuvant
KW - PAM50
KW - Tumor-infiltrating lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85014594946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014594946&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdw262
DO - 10.1093/annonc/mdw262
M3 - Article
AN - SCOPUS:85014594946
VL - 27
SP - 1867
EP - 1873
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 10
ER -